Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2023-08-01 Epub Date: 2023-08-23 DOI:10.2217/pgs-2023-0109

Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa, Miriam Saiz-Rodríguez

{"title":"Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.","authors":"Noelia Pérez-Gómez, María Dolores Fernández-Ortega, Miren Elizari-Roncal, Estefanía Santos-Mazo, Laura de la Maza-Pereg, Sara Calvo, Raquel Alcaraz, Antonio Sanz-Solas, Raquel Vinuesa, Miriam Saiz-Rodríguez","doi":"10.2217/pgs-2023-0109","DOIUrl":null,"url":null,"abstract":"Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, SLC47A1 rs2289669 A/A and SLC22A4 rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. SLC47A1 rs2289669 G/A genotype influenced glucose levels at 6 months, while SLC29A4 rs3889348 A/A, SLC47A1 rs2289669 A/A, SLC22A4 rs1050152 C/T and SLC47A2 rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, ABCB1 rs2032582 C/A and ABCG2 rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"651-663"},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2023-0109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Metformin, a hypoglycemic drug for Type 2 diabetes mellitus, shows variability in pharmacokinetics and response due to membrane transporters. This study followed 34 Type 2 diabetes mellitus patients on metformin treatment. Genetic variants in 11 metformin transport-related genes were analyzed, revealing associations. Specifically, SLC47A1 rs2289669 A/A and SLC22A4 rs1050152 T/T genotypes correlated with glycated hemoglobin values at 6 months. SLC47A1 rs2289669 G/A genotype influenced glucose levels at 6 months, while SLC29A4 rs3889348 A/A, SLC47A1 rs2289669 A/A, SLC22A4 rs1050152 C/T and SLC47A2 rs12943590 A/A genotypes were linked to glucose levels at 12 months. Additionally, ABCB1 rs2032582 C/A and ABCG2 rs2231137 C/T genotypes impacted cholesterol levels at 12 months. These findings shed light on metformin response determinants, offering insights for further research.

查看原文本刊更多论文

影响二甲双胍治疗2型糖尿病疗效的临床和药物遗传学因素的鉴定。

二甲双胍是一种治疗2型糖尿病的降血糖药物，由于膜转运蛋白的存在，其药代动力学和反应存在差异。本研究跟踪观察了34名接受二甲双胍治疗的2型糖尿病患者。对11个二甲双胍转运相关基因的遗传变异进行了分析，揭示了相关性。具体而言，SLC47A1 rs2289669 A/A和SLC22A4 rs1050152 T/T基因型与6个月时的糖化血红蛋白值相关。SLC47A1 rs2289669 G/A基因型影响6个月时的血糖水平，而SLC29A4 rs3889348 A/A、SLC47A2 rs2289669A、SLC22A4 rs1050152 C/T和SLC47A2rs12943590 A/A基因型与12个月时血糖水平相关。此外，ABCB1 rs2032582 C/A和ABCG2 rs2231137 C/T基因型在12个月时影响胆固醇水平。这些发现揭示了二甲双胍反应的决定因素，为进一步的研究提供了见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.